Stavra A Xanthakos1, Todd M Jenkins2, David E Kleiner3, Tawny W Boyce4, Reena Mourya5, Rebekah Karns6, Mary L Brandt7, Carroll M Harmon8, Michael A Helmrath2, Marc P Michalsky9, Anita P Courcoulas10, Meg H Zeller11, Thomas H Inge2. 1. Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: Stavra.xanthakos@cchmc.org. 2. Division of Pediatric Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio. 3. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 4. University of New Mexico Cancer Center, Biostatistics Shared Resource, Albuquerque, New Mexico. 5. Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. 6. Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio. 7. Division of Pediatric Surgery, Texas Children's Hospital, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas. 8. Division of Pediatric Surgery, Women & Children's Hospital of Buffalo, University of Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York. 9. Department of Pediatric Surgery, The Ohio State University College of Medicine and Nationwide Children's Hospital, Columbus, Ohio. 10. Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 11. Division of Behavioral Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract
BACKGROUND & AIMS: Little is known about the prevalence of nonalcoholic fatty liver disease (NAFLD) among severely obese adolescents or factors that determine its development. We investigated the prevalence of NAFLD in a multicenter cohort of adolescents undergoing bariatric surgery and the factors associated with it. METHODS: We enrolled 242 adolescents undergoing bariatric surgery between March 2007 and February 2012 at 5 tertiary care centers into a multicenter, prospective observational cohort study. Intraoperative core liver biopsies were collected from 165 subjects; 17 were excluded because of insufficient liver tissue or use of hepatotoxic medications, so 148 remained in the study (mean age, 16.8 ± 1.6 years; median body mass index = 52 kg/m(2)). Liver tissues were analyzed by histology using validated criteria. Hepatic gene expression was analyzed in 67 samples. RESULTS: NAFLD was present in 59% of this predominantly female (72%), white (68%), non-Hispanic (91%) cohort. Of subjects with NAFLD, 24% had borderline and 10% had definite nonalcoholic steatohepatitis (NASH). Mild fibrosis (stage 2 or lower) was observed in 18% of liver biopsies and stage 3 was observed in 0.7%, but cirrhosis was not detected. Dyslipidemia was present in 78% of subjects, hypertension in 44%, and diabetes in 14%. More severe NAFLD was associated with increasing levels of alanine aminotransferase, fasting glucose level, hypertension (each P < .01), and white blood cell count (P = .04). Only diabetes was associated with detection of fibrosis (odds ratio = 3.56; 95% confidence interval: 1.93-6.56). Microarray analysis associated presence of NASH with altered expression of genes that regulate macrophage chemotaxis, cholesterol absorption, and fatty acid binding. CONCLUSIONS: More than half of adolescents undergoing bariatric surgery in this cohort had NAFLD, yet the prevalence of severe or fibrotic NASH was low. Increasing severity of NAFLD was associated with level of alanine aminotransferase and cardiometabolic risk factors, but not body mass index. Based on gene expression analysis, borderline and definite NASH were associated with abnormal immune function, intestinal cholesterol absorption, and lipid metabolism.
BACKGROUND & AIMS: Little is known about the prevalence of nonalcoholic fatty liver disease (NAFLD) among severely obese adolescents or factors that determine its development. We investigated the prevalence of NAFLD in a multicenter cohort of adolescents undergoing bariatric surgery and the factors associated with it. METHODS: We enrolled 242 adolescents undergoing bariatric surgery between March 2007 and February 2012 at 5 tertiary care centers into a multicenter, prospective observational cohort study. Intraoperative core liver biopsies were collected from 165 subjects; 17 were excluded because of insufficient liver tissue or use of hepatotoxic medications, so 148 remained in the study (mean age, 16.8 ± 1.6 years; median body mass index = 52 kg/m(2)). Liver tissues were analyzed by histology using validated criteria. Hepatic gene expression was analyzed in 67 samples. RESULTS: NAFLD was present in 59% of this predominantly female (72%), white (68%), non-Hispanic (91%) cohort. Of subjects with NAFLD, 24% had borderline and 10% had definite nonalcoholic steatohepatitis (NASH). Mild fibrosis (stage 2 or lower) was observed in 18% of liver biopsies and stage 3 was observed in 0.7%, but cirrhosis was not detected. Dyslipidemia was present in 78% of subjects, hypertension in 44%, and diabetes in 14%. More severe NAFLD was associated with increasing levels of alanine aminotransferase, fasting glucose level, hypertension (each P < .01), and white blood cell count (P = .04). Only diabetes was associated with detection of fibrosis (odds ratio = 3.56; 95% confidence interval: 1.93-6.56). Microarray analysis associated presence of NASH with altered expression of genes that regulate macrophage chemotaxis, cholesterol absorption, and fatty acid binding. CONCLUSIONS: More than half of adolescents undergoing bariatric surgery in this cohort had NAFLD, yet the prevalence of severe or fibrotic NASH was low. Increasing severity of NAFLD was associated with level of alanine aminotransferase and cardiometabolic risk factors, but not body mass index. Based on gene expression analysis, borderline and definite NASH were associated with abnormal immune function, intestinal cholesterol absorption, and lipid metabolism.
Authors: Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo Journal: Lancet Date: 2014-11-07 Impact factor: 79.321
Authors: David E Kleiner; Paul D Berk; Jesse Y Hsu; Anita P Courcoulas; David Flum; Saurabh Khandelwal; John Pender; Alfons Pomp; James Roerig; Laura L Machado; Bruce M Wolfe; Steven H Belle Journal: Semin Liver Dis Date: 2014-04-29 Impact factor: 6.115
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Janey S A Pratt; Carine M Lenders; Emily A Dionne; Alison G Hoppin; George L K Hsu; Thomas H Inge; David F Lawlor; Margaret F Marino; Alan F Meyers; Jennifer L Rosenblum; Vivian M Sanchez Journal: Obesity (Silver Spring) Date: 2009-02-19 Impact factor: 5.002
Authors: Cynthia A Moylan; Herbert Pang; Andrew Dellinger; Ayako Suzuki; Melanie E Garrett; Cynthia D Guy; Susan K Murphy; Allison E Ashley-Koch; Steve S Choi; Gregory A Michelotti; Daniel D Hampton; Yuping Chen; Hans L Tillmann; Michael A Hauser; Manal F Abdelmalek; Anna Mae Diehl Journal: Hepatology Date: 2013-12-13 Impact factor: 17.425
Authors: Thomas H Inge; Meg H Zeller; Todd M Jenkins; Michael Helmrath; Mary L Brandt; Marc P Michalsky; Carroll M Harmon; Anita Courcoulas; Mary Horlick; Stavra A Xanthakos; Larry Dolan; Mark Mitsnefes; Sean J Barnett; Ralph Buncher Journal: JAMA Pediatr Date: 2014-01 Impact factor: 16.193
Authors: Jeffrey B Schwimmer; Anne Zepeda; Kimberly P Newton; Stavra A Xanthakos; Cynthia Behling; Erin K Hallinan; Michele Donithan; James Tonascia Journal: PLoS One Date: 2014-11-24 Impact factor: 3.240
Authors: Marc P Michalsky; Thomas H Inge; Todd M Jenkins; Changchun Xie; Anita Courcoulas; Michael Helmrath; Mary L Brandt; Carroll M Harmon; Mike Chen; John B Dixon; Elaine M Urbina Journal: Pediatrics Date: 2018-01-08 Impact factor: 7.124
Authors: Dennis M Hedderich; Till Hasenberg; Stefan Haneder; Stefan O Schoenberg; Özlem Kücükoglu; Ali Canbay; Mirko Otto Journal: Obes Surg Date: 2017-07 Impact factor: 4.129
Authors: R Ellen Jones; Ann Ming Yeh; Neerajah Kambham; Marwa Abu El Haija; Janey Pratt; Matias Bruzoni Journal: Obes Surg Date: 2020-01 Impact factor: 4.129
Authors: Elizabeth L Yu; Shahrokh Golshan; Kathryn E Harlow; Jorge E Angeles; Janis Durelle; Nidhi P Goyal; Kimberly P Newton; Mary Catherine Sawh; Jonathan Hooker; Ethan Z Sy; Michael S Middleton; Claude B Sirlin; Jeffrey B Schwimmer Journal: J Pediatr Date: 2018-12-14 Impact factor: 4.406
Authors: Lindel C Dewberry; Anahita Jalivand; Resmi Gupta; Todd M Jenkins; Andrew Beamish; Thomas H Inge; Anita Courcoulas; Michael Helmrath; Mary L Brandt; Carroll M Harmon; Mike Chen; John B Dixon; Margaret Zeller; Marc P Michalsky Journal: Obes Surg Date: 2020-06 Impact factor: 4.129
Authors: Ramon Vilallonga; José Manuel Moreno Villares; Diego Yeste Fernández; Raquel Sánchez Santos; Felipe Casanueva Freijo; Francisco Santolaya Ochando; Nuria Leal Hernando; Albert Lecube Torelló; Luis Antonio Castaño González; Albert Feliu; Gontrand Lopez-Nava; Dolores Frutos; Felipe de la Cruz Vigo; Antonio J Torres Garcia; Juan Carlos Ruiz de Adana Journal: Obes Surg Date: 2017-04 Impact factor: 4.129
Authors: Janey S A Pratt; Allen Browne; Nancy T Browne; Matias Bruzoni; Megan Cohen; Ashish Desai; Thomas Inge; Bradley C Linden; Samer G Mattar; Marc Michalsky; David Podkameni; Kirk W Reichard; Fatima Cody Stanford; Meg H Zeller; Jeffrey Zitsman Journal: Surg Obes Relat Dis Date: 2018-03-23 Impact factor: 4.734